Hemophilia Treatment Market 2020 by industry trends, statistics, key companies growth and regional forecast

Hemophilia Treatment Market report offers in-depth analysis of the industry size, share, major segments, and different geographic regions, forecast for the next five years, key market players, and premium industry trends. It also focuses on the key drivers, restraints, opportunities and industry challenges.

Global hemophilia treatment market is expected to accumulate considerable returns over the period of study due to the increasing cases of genetic abnormalities and the surging prevalence of hemophilia. A rare bleeding disorder, hemophilia causes incessant bleeding after a surgery or an injury owing to the delay in blood clotting. Optimum care and reliable treatment is considered crucial to prevent serious consequences.

World Federation of Hemophilia states that in the year 2016, the total cases of hemophilia across the globe stood at 184,723. The U.S. Center for Disease Control and Prevention recommends patients suffering from Hemophilia to opt for a treatment center in order to seek optimal care and necessary health education in order to stay healthy.

Request for a sample copy of this report @ https://www.decresearch.com/request-sample/detail/2772

Reportedly, the average age for the diagnosis of hemophilia is 1 month for severe hemophilia, 8 months in moderate cases, and 36 months for mild hemophilia cases. The rising deployment of Hemophilia Treatment Center globally will supplement the adoption of therapies. It is projected that global hemophilia treatment market size will reach USD 14.8 billion in annual value by 2025.

The global hemophilia treatment market share is likely to witness a major upsurge in years ahead, due to the robust acceptance of prophylaxis treatment and accelerating R&D activities by key market players across the globe.

Despite the favorable growth environment, the market is likely to encounter several challenges, including high prices of hemophilia drugs. Moreover, inadequate treatment of patients, alongside a lack of awareness about hemophilia management in underdeveloped and developing economies, may create roadblocks to the global market expansion in years ahead.

Based on product, the recombinant factor concentrates segment is poised to exhibit a growth rate of 5% through 2025, as a result of low disease transmission risks and its prevention of viral infection. Additionally, the product is capable of increasing the replacement therapy safety.

In terms of segmentation by disease, the hemophilia A segment recorded a revenue worth $6,743.7 million in 2018, which is attributable to high prevalence of hemophilia disorder in developing and underdeveloped countries.

With regards to the treatment spectrum, the global hemophilia treatment market from the prophylaxis treatment segment registered remuneration of $7,219.9 million in 2018 and is set to account for a major market share over the forecast spell, which can be credited to its effectiveness in treating bleeding episodes and joint pain.

In case of drug class, the coagulation factors segment was valued at $9,948.3million revenue in 2018, owing to its escalating adoption in replacement therapy to cater to the increasing incidence of moderate to severe hemophilia.

Moreover, the injectables route of administration segment is projected to exhibit a 5% growth rate through 2025, due to the shifting preferences of patients to quick mode of drug administration.

The global hemophilia treatment market from the adult segment recorded revenue worth $6,778.2 million in 2018, as adult patients have high chances of developing moderate to severe hemophilia. As per authentic reports, over 65% of the patients diagnosed with hemophilia are adults.

Based on end-use, the hemophilia treatment centers segment is poised to register a growth rate of 4.6% through 2025, which can be attributed to the enhanced care services provided by these centers as compared to clinics and hospitals.

From a regional perspective, the U.S. hemophilia treatment market recorded remuneration worth $3,539.3million in 2018, due to the availability of favorable reimbursement policies in the region.

Additionally, the India hemophilia treatment market is projected to expand at a 9.2% growth rate through 2025. The regional market growth can be credited to the increasing healthcare spending and government initiatives to educate people about hemophilia diagnosis.

The competitive landscape of the hemophilia treatment market comprises of companies such as Genentech, Biotest AG, Swedeish Orphan Biovitrum AB, and Sanofi SA, among others. These firms are focusing on expanding their stance in the global market through various strategies including partnerships and innovative product launches.

To illustrate, in November 2019, Highmark announced a partnership with care providers across Pennsylvania, namely the Hemophilia Center, Soleo Health, and Option Care Health, for its members to obtain an optimal, effective hemophilia medication that meets the rigorous performance standards. The company’s endeavor is also aimed at reducing the drug wastes and higher costs associated with fraud. 

Browse full table of contents (TOC) of this report @ https://www.decresearch.com/toc/detail/hemophilia-treatment-market

Partial Chapter of the Table of Content 

Chapter 4. Hemophilia Treatment Market, By Disease

4.1. Global hemophilia treatment market share by disease, 2018 & 2025

4.2. Hemophilia A

4.2.1. Market size, by region, 2014 – 2025 (USD Million)

4.2.2. Severe

4.2.2.1. Market size, by region, 2014 – 2025 (USD Million)

4.2.3. Moderate

4.2.3.1. Market size, by region, 2014 – 2025 (USD Million)

4.2.4. Mild

4.2.4.1. Market size, by region, 2014 – 2025 (USD Million)

4.3. Hemophilia B

4.3.1. Market size, by region, 2014 – 2025 (USD Million)

4.3.2. Severe

4.3.2.1. Market size, by region, 2014 – 2025 (USD Million)

4.3.3. Moderate

4.3.3.1. Market size, by region, 2014 – 2025 (USD Million)

4.3.4. Mild

4.3.4.1. Market size, by region, 2014 – 2025 (USD Million)

4.4. Others

4.4.1. Market size, by region, 2014 – 2025 (USD Million)

Chapter 5. Hemophilia Treatment Market, By Product

5.1. Global hemophilia treatment market share by product, 2018 & 2025

5.2. Recombinant Factor Concentrates

5.2.1. Market size, by region, 2014 – 2025 (USD Million)

5.2.2. Factor VIII

5.2.2.1. Market size, by region, 2014 – 2025 (USD Million)

5.2.3. Factor IX

5.2.3.1. Market size, by region, 2014 – 2025 (USD Million)

5.3. Plasma-derived Factor Concentrates

5.3.1. Market size, by region, 2014 – 2025 (USD Million)

5.3.2. Factor VIII

5.3.2.1. Market size, by region, 2014 – 2025 (USD Million)

5.3.3. Factor IX

5.3.3.1. Market size, by region, 2014 – 2025 (USD Million)

5.4. Extended Half-life Products

5.4.1. Market size, by region, 2014 – 2025 (USD Million)

5.4.2. Factor VIII

5.4.2.1. Market size, by region, 2014 – 2025 (USD Million)

5.4.3. Factor IX

5.4.3.1. Market size, by region, 2014 – 2025 (USD Million)

5.5. Others

5.5.1. Market size, by region, 2014 – 2025 (USD Million)